Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags Response Assessment in Neuro-Oncology

Tag: Response Assessment in Neuro-Oncology

Rare Pediatric Disease Designation for ABT-414 for the Treatment of a...

Sonia Portillo
The U.S. Food and Drug Administration (FDA) has a granted Rare Pediatric Disease Designation for AbbVie's ABT-414, an investigational antibody-drug conjugate (ADC) targeting the...

ABT-414 Shows Encouraging Phase I Results in Monotherapy in Patients with...

Peter Hofland
Safety and preliminary efficacy data from a phase I study of ABT-414 (AbbVie) – an investigational antibody drug conjugate or ADC for the treatment of...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X